You are here: Industry Insights > GlobalData

News List

Regenerative medicine market to reach $16.4 bn in 2026: GlobalData expresspharma
December 07, 2020
There are currently 53 marketed RM products and 175 RM pipeline agents in development in the eight major markets.
China has highest PD-1/PD-L1 combination immuno-oncology therapies clinical trials growth: GlobalData expresspharma
December 01, 2020
Between 2017 and 2019, the number of clinical trials initiated for PD-1/PD-L1 targeted combination therapies increased substantially, which continued in 2020, albeit with a significantly slower rate possibly due to the global COVID-19 pandemic.
Half of top 20 global innovative pharma companies MCap reported positive growth in Q3 2020- GlobalData expresspharma
November 27, 2020
Half of the companies in a ranking of top 20 global innovative pharmaceutical firms by data and analytics company GlobalData reported positive market capitalization (MCap) growth in Q3, with Pfizer and Daiichi Sankyo Co reporting double-digit percentage..
Successive drug launches will drive growth of NASH market in seven major markets: GlobalData expresspharma
November 24, 2020
The NASH market will undergo a very rapid growth, at a compound annual growth rate (CAGR) of 68.8 per cent from 2019 to 2029.
COVID-19 vaccines production driving contract service agreements expresspharma
November 19, 2020
Most contract manufacturing service agreements are for recombinant vector vaccines, followed by subunit vaccines.
COVID-19 forced pharma to shuffle technology investment priorities: GlobalData expresspharma
November 12, 2020
Social media and cloud computing became the most dominant technologies for current investments for pharma in 2020.
Ease of administration and dual protection can drive novel intranasal vaccine adoption: GlobalData expresspharma
November 11, 2020
Late-stage clinical trials of intranasal COVID-19 vaccines are expected to begin in India in the coming months.
COVID-19 is driving more supplier redundancy expresspharma
November 06, 2020
Contract development and manufacturing organisations (CDMOs) are busier than ever, and their work will increase as the pandemic prompts pharma companies to increase redundancy in the supply chain, says GlobalData.
Disappointing SOLIDARITY results for remdesivir likely due to trial differences and not the drug: GlobalData expresspharma
November 06, 2020
The SOLIDARITY trial did show that large-scale international trials are possible during a pandemic with the possibility of drawing conclusions at a rapid pace, as soon as six months.
Skills and talents deficit poses biggest challenge to digital transformation in pharma expresspharma
November 06, 2020
The success of digital transformation will heavily depend on employees being on board and adapting as digital transformation process is a never-ending change.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page